Navigation Links
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Date:6/13/2008

Patients on Treatment Also Experienced Improved Physical Functioning

INDIANAPOLIS, June 13 /PRNewswire-FirstCall/ -- New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment that lasted throughout the 13-week trial.(1) Results from the study of 231 patients were presented today at the annual congress of the European League Against Rheumatism (EULAR) in Paris, France.

Duloxetine showed statistically significant improvement in pain associated with osteoarthritis of the knee according to the primary efficacy measure of mean 24-hour average pain scores. Fifty-nine percent of duloxetine-treated patients experienced a 30 percent improvement in pain compared with 45 percent of patients taking placebo. Forty-seven percent of duloxetine-treated patients experienced a 50 percent improvement in pain compared with 29 percent of placebo-treated patients.

Treatment with duloxetine also was associated with improved patient outcomes compared with placebo as measured by the Patient Global Impressions of Improvement (PGI-I) and physical functioning as measured by the Western Ontario and McMaster Universities (WOMAC) physical functioning subscale.

In this study, the most common adverse events (occurred at a rate of greater than or equal to 3 percent and at least twice the rate of placebo) were nausea, fatigue, somnolence, dizziness, hypertension, constipation and decreased libido.

"These data are important because it's the first time duloxetine has been studied in a large, placebo-controlled trial in what's classified as an inflammatory disease state," said Amy Chappell, M.D., lead study author and medical fellow II, Eli Lilly and Company. "Although the exact mechanism of action is unknown, this study may prov
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
2. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
3. Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients
4. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
5. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
6. New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
7. Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
10. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
11. Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... The Netherlands and JOHANNESBURG, November 25 /PR...sion and Pyxis Discovery announced today,that they...market both,companies, services. , Pyxis,...covery expertise,will be coupled with iThemba,s se...chemistry support to projects identified through P...
(Date:11/24/2009)...Nov. 24 ,, WHAT: Rom Houbens,... years following an auto accident, was actually fu...he subject of a Good Morning America segment. The...ustrate how people with Locked-in Syndrome and oth...: Good Morning America -- Tuesday, November 24 ...
(Date:11/24/2009)...v. 24 Anadys Pharmaceuti...t will present at the 21st Annual Piper Jaffray He...t 9:00 a.m. EST (6:00 a.m. PST). The conference i...Worland, Ph.D., President and Chief Executive Offi...and its clinical development programs, ANA598 and ...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 1Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 3Baxa Announces IntelliFlowRx 28TM 29 to Become DoseEdge 28TM 29 Dose Management System 5463 1Baxa Announces IntelliFlowRx 28TM 29 to Become DoseEdge 28TM 29 Dose Management System 5463 2
... Pa., Sept. 19 Wyeth,Pharmaceuticals, a division ...Phase 3 fracture data for bazedoxifene, a selectiv...iety for Bone and Mineral Research Annual,Meeting....ene 20 mg and 40,mg significantly reduced the rela... and 37 percent, respectively, compared with place...
...pt. 19 Alba Therapeutics Corporation today,announ...eek Phase IIb trial,with oral AT-1001, an inhibito...maintenance of remission in patients with Celiac D...bo-controlled, dose ranging study will,evaluate th...CD subjects,during a six-week gluten challenge, wh...
Other Medicine Technology:Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 2Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 3Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis 4Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease 2
(Date:11/26/2009)...25 years, the number of Americans living with diab...ion in 2009 to 44.1 million in 2034. Over the same...rising from $113 billion to $336 billion, even wit...chers based at the University of Chicago report in...mber of those with diabetes covered by Medicare wi...
(Date:11/26/2009)...ger thrill when on an emotional rollercoaster, stu...y News) -- Call it the fear factor meets the jubil...ctators -- especially those who root for the winni... a closely contested match and victory was in doub..., Chew on that this Thanksgiving weekend as you,...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a...rolina, today announced the expansion of its servi...entist, Dr. Doug Macmillan. , ...ntal is pleased to announce that Dr. Doug Macmilla...mpleted an additional advanced training seminar. ...
(Date:11/25/2009)...INA, Minn., Nov. 25 Whe...their dentist. But a chiropractor can also give p...poral-Mandibular Joint, which is where your jaw (m...al bone). ,, The most common symptoms associat...cking or popping of the jaw. But many other sympt...
(Date:11/25/2009)...ORONTO and CALGARY, Nov. 25 /PRNewswire/ - Sentine...ic Resonance Imaging (MRI) coils and software and ...tware enabling technologies, have introduced a web...tion software. ,, This innovative interface is ...dical imaging offering in the market. Calgary Scie...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...ead regions' in the brain that could be responsibl...by Karolina Kluk, a Cambridge University student. ...opment of individualized hearing aids for children...not be used with babies. The new electrophysiologi...
...nal examination of a child, to determine the locat...gn of abuse. // This was discussed in the American...in Seattle recently. Retina is a light sensiti...e. A wide variety of conditions such as falls...
...ecalled from the market as stated by the FDA due t...cans. // So this brand would not be sold in market...ant formula, Mead Johnson Nutritionals of EVANSVIL...company for the recall is public health concern. A...
...s, preventing the spread of the deadly virus H5N1,...he Eastern past of France. // The farm in Versaill...y turkeys, was just 200mts away from the lake wher...nion farm has got the bird-flu infection. Nearly 8...
... against indiscriminate antibiotic use, saying th...e prescribed inappropriately. //This issue figure...microbials annual scientific discussion meeting in...ncrease in drug-resistant infections. Prof Tur...
...e complication following coronary artery bypass gr...enon gas, a new study has found. // The results o...d in Anesthesiology journal. The researchers...lopment of new treatments for diseases associated ...
Other Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2
...ion via the pelvic nerves has proven to be an effe.... Through the use of mild electrical stimulation, ...d to encourage urinary control and continence. Zyn... a tool to aid in the treatment and alleviate the ...
High Dose Rate (HDR) Treatment System
...r Template Set is the HDR solution which duplicate...e. The template set consists of a small grid style...s placed in a Stepper Holder with variable ultraso...ble for different ultrasound stepper devices. The ...
Disposable Template
Medicine Products: